Claims for Patent: 5,932,545

Summary for Patent: 5,932,545

Title:	Antiangiogenic drug to treat cancer, arthritis and retinopathy
Abstract:	Peptides having the formula:T-Gly-Val-D-Ile-Thr-Arg-Ile-U,V-Gly-D-Val-Ile-D-Thr-D-Arg-D-Il e-W,X-D-Arg-D-Ile-D-Arg-D-Thr-lle-D-Val-Y, andZ-Gly-Val-Ile-Thr-Arg-Ile-Uwherein T is absent or is selected from N-protecting group and a polypeptide of up to 12 amino acid residues optionally terminated with a N-protecting group; U is selected from Arg and Arg-NR1R2 wherein R1 and R2 are independently selected from hydrogen and alkyl of one to four carbon atoms; V is absent or a N-protecting group; W is selected from D-Arg and D-Arg-NR1R2; X is absent or a N-protecting group; Y is selected from Gly and Gly-NR1R2; and Z is 1-12 amino acid residues optionally terminated with a N-protecting group wherein at least one of the amino acid residues is a D-amino acid residue inhibit angiogenesis and are useful in the treatment of disease states such as cancer, arthritis, macular degeneration and diabetic retinopathyin which angiogenesis plays a role.
Inventor(s):	Jack Henkin, Noel P. Bouck, David W. Dawson, Andrew J. Schneider
Assignee:	Northwestern University , AbbVie Inc
Application Number:	US09/039,682

Details for Patent 5,932,545

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	March 25, 2003		2018-03-16
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	July 31, 2014		2018-03-16